Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Neoantigen Vaccine vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) in Patients With Metastatic Triple Negative Breast Cancer
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 15 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 15 Dec 2018.
- 07 Sep 2018 Planned initiation date changed from 25 Aug 2018 to 1 Oct 2018.